Oxford BioDynamics PLC Presents at the Diabetes Asia 2017 Conference
October 13 2017 - 2:00AM
RNS Non-Regulatory
TIDMOBD
Oxford BioDynamics PLC
13 October 2017
13 October 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics presents at the Diabetes Asia 2017
Conference
EpiSwitch(TM) successful in stratifying patients into different
stages of type 2 diabetes
Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology
company focused on the discovery and development of epigenetic
biomarkers based on regulatory genome architecture, for use within
the pharmaceutical and biotechnology industry, today announces that
it has presented a poster at The Diabetes Asia 2017 Conference,
12-15 October 2017 in Kuala Lumpur, Malaysia.
The poster entitled: "Glycaemic Progression Study Among
Population in Penang, Malaysia" was presented from 2.00pm-3.30pm
local time on 12 October 2017.
Type 2 diabetes mellitus (T2D) is a fast growing health threat
with increasing prevalence in Asian populations. From 2006 to 2011,
the prevalence of T2D in Malaysia increased by 31%(1) .
Interestingly, most patients with T2D pass through a 'pre-diabetes'
phase, where the biochemical threshold for diagnosis has not been
reached. Clinical trials have shown that the risk of progression to
T2D can be reduced in the pre-diabetes phase.
In this study, 270 people were separated into groups dependent
on their diabetes status (healthy, pre-diabetes, diabetes
treatment-naive and diabetes with treatment). The glycaemic
progression of these individuals was followed-up at six months.
After six months, it was found that 44% of participants in the
pre-diabetes stage regressed to the healthy stage, however only 4%
of participants with diabetes regressed to the healthy stage. Using
epigenetic biomarkers identified by OBD's EpiSwitch(TM) technology,
individuals could be accurately stratified to identify those in the
pre-diabetes phase, the phase at which diabetes is most likely to
be prevented.
Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford
BioDynamics, commented:
"This study demonstrates that there is considerable clinical
utility in using our EpiSwitch(TM) technology to identify those at
the pre-diabetic phase, and could be a powerful tool in tackling
the overall increasing prevalence of diabetes. Our EpiSwitch(TM)
technology has been shown to help stratify, in a rapid and robust
way, individuals whether healthy, pre-diabetic or diabetic. We now
can identify and concentrate on the individuals at risk of
developing the disease; building prognostic stratifications,
something that is not currently possible with other biomarker
approaches. Type 2 diabetes is a classic example of an epigenetic
disease, with a severe impact on healthcare in many countries
around the world. We believe that the OBD epigenetic biomarker
technology opens new healthcare opportunities for the monitoring
and profiling of type 2 diabetes patients. It could help alleviate
this particular health threat in Malaysia, and set a successful
precedent for other countries and national healthcare
institutions."
Reference
1. National Diabetes Registry Report, 2009-2012, Volume 1
For further details contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar, CEO
Paul Stockdale, CFO
Stifel Nicolaus Europe Limited +44 (0)20 7710 7600
Nominated Advisor and Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
Shore Capital +44 (0)20 7408 4090
Joint Broker
Stephane Auton
Edward Mansfield
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations
Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFFIFMEFWSEIS
(END) Dow Jones Newswires
October 13, 2017 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024